With £96 million Series A financing, Lifescience company developer Syncona has launched Beacon Therapeutics Holdings, a leading ophthalmic gene therapy company focused on restoration and improvement of vision of patients with retinal diseases. Click to read more.
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New leading gene therapy company created combining late-stage X-linked retinitis pigmentosa program from AGTC, a preclinical program spun out from the University of Oxford and a second. | June 12, 2023
Beacon of Light: Retinal Gene Therapy Developer Launches with $120M genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.